Cargando…

Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study

BACKGROUND: Based on a prognostic scoring system (P score) proposed by us recently, this retrospective large population-based and propensity score-matched (PSM) study focused on predicting the survival benefit of adjuvant CT in stage II disease. METHODS: Patients diagnosed with stage II colon cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qi, Shan, Zezhi, Luo, Dakui, Zhang, Sheng, Li, Qingguo, Li, Xinxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945037/
https://www.ncbi.nlm.nih.gov/pubmed/33718134
http://dx.doi.org/10.3389/fonc.2021.574772
_version_ 1783662785356365824
author Liu, Qi
Shan, Zezhi
Luo, Dakui
Zhang, Sheng
Li, Qingguo
Li, Xinxiang
author_facet Liu, Qi
Shan, Zezhi
Luo, Dakui
Zhang, Sheng
Li, Qingguo
Li, Xinxiang
author_sort Liu, Qi
collection PubMed
description BACKGROUND: Based on a prognostic scoring system (P score) proposed by us recently, this retrospective large population-based and propensity score-matched (PSM) study focused on predicting the survival benefit of adjuvant CT in stage II disease. METHODS: Patients diagnosed with stage II colon cancer (N = 73397) were identified from the Surveillance, Epidemiology, and End Results database between January 1, 1988 and December 31, 2005 and divided into the CT and non-CT groups. PSM balanced the patient characteristics between the CT and non-CT groups. RESULTS: The magnitude of CSS improvement among patients treated with adjuvant CT was significantly associated with the P score, score 8 [hazard ratio (HR) = 0.580, 95% confidence interval (CI) = 0.323–1.040, P = 0.067] was associated with a much higher increased CSS benefit among patients treated with adjuvant CT as compared to score 2* (*, including scores 0, 1, and 2; HR = 1.338, 95% CI = 1.089–1.644, P = 0.006). CONCLUSIONS: High P scores were demonstrated to be associated with superior survival benefit of adjuvant CT. Therapy decisions of adjuvant CT in stage II colon cancer could be tailored on the basis of tumor biology, patient characteristics and the P score.
format Online
Article
Text
id pubmed-7945037
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79450372021-03-11 Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study Liu, Qi Shan, Zezhi Luo, Dakui Zhang, Sheng Li, Qingguo Li, Xinxiang Front Oncol Oncology BACKGROUND: Based on a prognostic scoring system (P score) proposed by us recently, this retrospective large population-based and propensity score-matched (PSM) study focused on predicting the survival benefit of adjuvant CT in stage II disease. METHODS: Patients diagnosed with stage II colon cancer (N = 73397) were identified from the Surveillance, Epidemiology, and End Results database between January 1, 1988 and December 31, 2005 and divided into the CT and non-CT groups. PSM balanced the patient characteristics between the CT and non-CT groups. RESULTS: The magnitude of CSS improvement among patients treated with adjuvant CT was significantly associated with the P score, score 8 [hazard ratio (HR) = 0.580, 95% confidence interval (CI) = 0.323–1.040, P = 0.067] was associated with a much higher increased CSS benefit among patients treated with adjuvant CT as compared to score 2* (*, including scores 0, 1, and 2; HR = 1.338, 95% CI = 1.089–1.644, P = 0.006). CONCLUSIONS: High P scores were demonstrated to be associated with superior survival benefit of adjuvant CT. Therapy decisions of adjuvant CT in stage II colon cancer could be tailored on the basis of tumor biology, patient characteristics and the P score. Frontiers Media S.A. 2021-02-24 /pmc/articles/PMC7945037/ /pubmed/33718134 http://dx.doi.org/10.3389/fonc.2021.574772 Text en Copyright © 2021 Liu, Shan, Luo, Zhang, Li and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Qi
Shan, Zezhi
Luo, Dakui
Zhang, Sheng
Li, Qingguo
Li, Xinxiang
Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study
title Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study
title_full Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study
title_fullStr Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study
title_full_unstemmed Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study
title_short Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study
title_sort associations of p score with real-world survival improvement offered by adjuvant chemotherapy in stage ii colon cancer: a large population-based longitudinal cohort study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945037/
https://www.ncbi.nlm.nih.gov/pubmed/33718134
http://dx.doi.org/10.3389/fonc.2021.574772
work_keys_str_mv AT liuqi associationsofpscorewithrealworldsurvivalimprovementofferedbyadjuvantchemotherapyinstageiicoloncanceralargepopulationbasedlongitudinalcohortstudy
AT shanzezhi associationsofpscorewithrealworldsurvivalimprovementofferedbyadjuvantchemotherapyinstageiicoloncanceralargepopulationbasedlongitudinalcohortstudy
AT luodakui associationsofpscorewithrealworldsurvivalimprovementofferedbyadjuvantchemotherapyinstageiicoloncanceralargepopulationbasedlongitudinalcohortstudy
AT zhangsheng associationsofpscorewithrealworldsurvivalimprovementofferedbyadjuvantchemotherapyinstageiicoloncanceralargepopulationbasedlongitudinalcohortstudy
AT liqingguo associationsofpscorewithrealworldsurvivalimprovementofferedbyadjuvantchemotherapyinstageiicoloncanceralargepopulationbasedlongitudinalcohortstudy
AT lixinxiang associationsofpscorewithrealworldsurvivalimprovementofferedbyadjuvantchemotherapyinstageiicoloncanceralargepopulationbasedlongitudinalcohortstudy